


DTW



I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Hon. Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this 22nd day of September, 2005.

By 
(Signature of person mailing)
Erica L. Smith
(Typed or printed name of person)

Patent Application
Docket No. PC25541A

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
PHILIP A. CARPINO

Serial No. 10/823,107
Filed on April 12, 2004

For: CANNABINOID RECEPTOR
LIGANDS AND USES THEREOF

Group Art Unit: 1625

Examiner: OWENS, AMELIA A

SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. 1.97; and 1.98, Applicant's agent wishes to draw the Examiner's attention to the reference listed on the attached PTO-FB-A820.

None of the following has been received: (i) a Notice of Allowance under §1.311, (ii) a final action under §1.113 on the merits or (iii) an action that otherwise closes prosecution in the application. However, a first office action on the merits has been received; therefore, authorization for payment of the requisite fee set forth in §1.17(p) is attached hereto.

The following four references were cited by the Examiner in an office action mailed on September 12, 2005 in the form of their abstracts:

PubMed ID No. 10469889: Barth, F., et al, "The Development of Cannabinoid Antagonists" Current Medicinal Chemistry, 6, 745-755 (1999).

CA 129: 49198: Duplantier, Allen J., et al., "7-Oxo-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridines as Novel Inhibitors of Human Eosinophil Phosphodiesterase" J Med Chem, 41 2268-2277 (1998).

CA 65: 123344: NL 6511645

CA 122: 239696: WO 95/01980 (Duplantier, AJ)

09/27/2005 SFELEKE1 00000051 161445 10823107
01 FC:1806 180.00 DA

The full references are being submitted to provide a complete record. In addition, the US equivalents for NL 6511645 are included: US Patent Nos. 3,340,269 and 3,365,459. Two current review articles are also included which describe the utility of cannabinoid receptor modulators (in particular, CB-1 receptor antagonists).

The Examiner is respectfully requested to indicate his or her consideration of the foregoing items by initialing, signing, and dating the accompanying PTO-FB-A820 and then returning a copy of the form to the undersigned.

The Commissioner is hereby authorized to charge the sum of \$180.00 to Deposit Account No. 16-1445 pursuant to C.F.R. § 1.17(p). The Commissioner is further authorized to charge any additional fees or credit any overpayment to Account No. 16-1445.

Respectfully Submitted By:

Date

September 22, 2005

Arlene K. Musser

Arlene K. Musser
Attorney for Applicant(s)
Registration No. 37,895

Pfizer Inc.
Patent Department, MS 8260-1611
Eastern Point Road
Groton, Connecticut 06340
(860) 715-0871

